Bradley Alford - Perrigo Company Independent Director

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;padding-top: 25px;;'>PC</div>
PRGO -- USA Stock  

Last Earning Announcement: 31st of December 2015  

  Director
Mr. Bradley A. Alford serves as Independent Director of the Company. Mr. Alford joined Advent International Corporationrationration, a global private equity firm, in 2014 as an Industry Advisor and moved to Operating Partner in March of 2016. From 2006 to 2013, Mr. Alford was Chairman and Chief Executive Officer of Nestl USA. Mr. Alford also served as CEO and President of Nestl Brands Company. He currently serves as a director of Avery Dennison Corporationrationration since April 2010 and previously served as a director of Conagra Brands, Inc. from July 2015 to September 2018. Throughout his career, Mr. Alford was focused on developing brands, initiatives to improve processes and facilitate best practices across an organization.
Age: 61  Director Since 2017      
353 1 709 4000  http://www.perrigo.com

Bradley Alford Latest Insider Activity

Perrigo Company Management Efficiency

Perrigo Company has return on total asset (ROA) of 2.63 % which means that it generated profit of $2.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 3.28 %, meaning that it created $3.28 on every $100 dollars invested by stockholders. Perrigo Company management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company currently holds 3.6 B in liabilities with Debt to Equity (D/E) ratio of 0.62, which is about average as compared to similar companies. Perrigo Company has a current ratio of 1.82, which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Joseph GoldsteinRegeneron Pharmaceuticals
1991
George SingRegeneron Pharmaceuticals
1988
Gregory NordenZoetis Inc
2013
Frances FergussonPfizer Inc
2009
Dan LittmanPfizer Inc
2018
Adriane BrownAllergan Plc
2017
Helen HobbsPfizer Inc
2011
Robert ScullyZoetis Inc
2013
William DoyleZoetis Inc
2015
Alan GarberVertex Pharmaceuticals Incorpor
2017
Michael GreenbergAllergan Plc
2018
Frank DAmelioZoetis Inc
2016
Sanjay KhoslaZoetis Inc
2013
Hans HaslerDr Reddys Laboratories
2016
Stephen SangerPfizer Inc
2009
Carol DavidsonAllergan Plc
2018
Leo PuriDr Reddys Laboratories
2018
Elaine UllianVertex Pharmaceuticals Incorpor
2011
James BloemAllergan Plc
2013
Omkar GoswamiDr Reddys Laboratories
2000
Patrick OSullivanAllergan Plc
2013

Company Summary

Perrigo Company plc manufactures and supplies over-the-counter health and wellness solutions in the United States, Europe, and internationally. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 11000 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 11,000 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
few days ago
Traded for 8.62
GM   
Sold over 100 shares of
few days ago
Traded for 25.24
XOM   
Sold over 60 shares of
few days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
few days ago
Traded for 28.82
MSFT   
Sold few shares of
few days ago
Traded for 206.26
Please check Your Equity Center. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page